Allurion Plummets 28.5% Amid NYSE Delisting Threat and Capital Struggles

Summary
• NYSE initiates delisting proceedings against Allurion (ALUR) for failing to meet $50M equity/market cap requirements
• FDA approval of gastric balloon system announced February 20, 2026, cited as catalyst for compliance plan
• Intraday price drops to $0.77 (52W low) amid 18.36M turnover surge

Shares of Allurion Technologies (ALUR) imploded on March 2, 2026, as the NYSE announced delisting proceedings over capitalization deficiencies. The stock traded as low as $0.77—matching its 52-week floor—amid a 28.5% intraday collapse. While the company claims FDA approval will catalyze compliance efforts, the immediate market reaction underscores severe liquidity risks and regulatory uncertainty.

NYSE Delisting Notice Sparks Liquidity Crisis
The NYSE's delisting notice triggered a liquidity vacuum as investors priced in the risk of reduced market access. Allurion's failure to maintain $50 million in stockholders' equity or market cap under Section 802.01B created a self-fulfilling prophecy: falling prices further eroded capitalization, deepening the breach. The company's announcement of a debt-for-preferred stock exchange and warrant inducement transaction on February 24, 2026, failed to reassure investors, who viewed these measures as insufficient to reverse the downward spiral. The 18.36M turnover (17.1% of float) reflects panic selling as shareholders anticipate delisting-related illiquidity.

Medical Device Sector Steadies as Allurion Crumbles
While Allurion's medical device peers remain stable—Medtronic (MDT) rose 0.12%—the sector's resilience highlights Allurion's unique regulatory and capital challenges. The FDA approval of its gastric balloon system could theoretically position Allurion as a disruptor in obesity care, but the delisting threat overshadows product potential. Unlike peers with diversified revenue streams, Allurion's reliance on capital markets makes it vulnerable to liquidity shocks.

Technical Deterioration and Capital Structure Risks
• 200-day average: $2.048 (far above current price)
• RSI: 52.17 (neutral but bearish bias)
• Bollinger Bands: Price at $0.8363 (near lower band at $0.8737)
• MACD: -0.0439 (bearish divergence)

The technical picture is dire: ALUR is trading 60% below its 200-day MA and within 5% of its 52W low. With no options liquidity and a 17.1% turnover rate, the stock exhibits classic short-term panic selling. Aggressive short-sellers could target the 200D support at $2.16, but the probability of a rebound is low given the delisting risk. Medtronic's 0.12% gain contrasts sharply with ALUR's collapse, suggesting sector investors remain focused on fundamentals rather than regulatory drama.

Backtest Allurion Stock Performance
The backtest of ALUR's performance after a -29% intraday plunge from 2022 to the present reveals mixed results. While the ETF has experienced some recovery, the overall returns have been negative. The 3-day win rate is 45.13%, the 10-day win rate is 39.28%, and the 30-day win rate is 40.39%, indicating that ALUR has a higher probability of positive returns in the short term. However, the maximum return during the backtest period was only -0.45%, which suggests that the ETF has struggled to recover from the significant intraday plunge.

Delisting Clock Ticks—Allurion's Survival Hinges on FDA Momentum
Allurion's appeal process buys time but offers no guarantee of NYSE survival. The FDA approval of its gastric balloon system is a critical catalyst, but commercialization timelines and capital-raising success will determine if the stock regains $1.00 support. Investors should monitor the March 3, 2026, NYSE committee review date and watch for a potential $0.80 breakdown. Medtronic's (MDT) 0.12% gain underscores the sector's resilience, but Allurion's unique liquidity crisis demands a binary outcome: either a successful capital raise or delisting. Position sizing should reflect the high-risk, high-reward nature of this trade.